Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.

Xiao Jian Han, Ling Fei Sun, Yuki Nishiyama, Bin Feng, Hiroyuki Michiue, Masaharu Seno, Hideki Matsui, Kazuhito Tomizawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A combination of molecular-targeted cancer imaging and therapy is an emerging strategy to improve cancer diagnosis and minimize the side effects of conventional treatments. Here, we generated a recombinant protein, EC1-GLuc-p53C, by fusing EC1 peptide, an artificial ligand of ErbB2, with Gaussia luciferase (GLuc) and a p53-activating peptide, p53C. EC1-GLuc-p53C was expressed and purified from E. coli BL21. In vitro experiments showed that EC1-GLuc-p53c was stable in luminescent activity and selectively targeted ErbB2-overexpressing BT474 cells for bioluminescence imaging. Moreover, the internalized EC1-GLuc-p53C in BT474 cells exerted its function to reactivate p53 and significantly inhibited cellular proliferation. In tumor-bearing mice, the ErbB2-targeted bioluminescence imaging and therapeutic effect of EC1-GLuc-p53C were also observed specifically in BT474 tumors but not in MCF7 tumors, which does not overexpress ErbB2. Thus, the present study demonstrates EC1-GLuc-p53C to be an effective theranostic reagent targeting ErbB2 for bioluminescence imaging and cancer therapy.

Original languageEnglish
Article numbere75288
JournalPLoS One
Volume8
Issue number9
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Bioluminescence
bioluminescence
Protein Transport
luciferase
Luciferases
image analysis
Imaging techniques
therapeutics
neoplasms
Neoplasms
Proteins
proteins
Tumors
Therapeutics
Bearings (structural)
peptides
Peptides
Therapeutic Uses
Theranostic Nanomedicine
Recombinant Proteins

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Han, X. J., Sun, L. F., Nishiyama, Y., Feng, B., Michiue, H., Seno, M., ... Tomizawa, K. (2013). Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. PLoS One, 8(9), [e75288].

Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. / Han, Xiao Jian; Sun, Ling Fei; Nishiyama, Yuki; Feng, Bin; Michiue, Hiroyuki; Seno, Masaharu; Matsui, Hideki; Tomizawa, Kazuhito.

In: PLoS One, Vol. 8, No. 9, e75288, 2013.

Research output: Contribution to journalArticle

Han, XJ, Sun, LF, Nishiyama, Y, Feng, B, Michiue, H, Seno, M, Matsui, H & Tomizawa, K 2013, 'Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.', PLoS One, vol. 8, no. 9, e75288.
Han, Xiao Jian ; Sun, Ling Fei ; Nishiyama, Yuki ; Feng, Bin ; Michiue, Hiroyuki ; Seno, Masaharu ; Matsui, Hideki ; Tomizawa, Kazuhito. / Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. In: PLoS One. 2013 ; Vol. 8, No. 9.
@article{09274c5e91e643a2ae6a3e39f71a2ec7,
title = "Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.",
abstract = "A combination of molecular-targeted cancer imaging and therapy is an emerging strategy to improve cancer diagnosis and minimize the side effects of conventional treatments. Here, we generated a recombinant protein, EC1-GLuc-p53C, by fusing EC1 peptide, an artificial ligand of ErbB2, with Gaussia luciferase (GLuc) and a p53-activating peptide, p53C. EC1-GLuc-p53C was expressed and purified from E. coli BL21. In vitro experiments showed that EC1-GLuc-p53c was stable in luminescent activity and selectively targeted ErbB2-overexpressing BT474 cells for bioluminescence imaging. Moreover, the internalized EC1-GLuc-p53C in BT474 cells exerted its function to reactivate p53 and significantly inhibited cellular proliferation. In tumor-bearing mice, the ErbB2-targeted bioluminescence imaging and therapeutic effect of EC1-GLuc-p53C were also observed specifically in BT474 tumors but not in MCF7 tumors, which does not overexpress ErbB2. Thus, the present study demonstrates EC1-GLuc-p53C to be an effective theranostic reagent targeting ErbB2 for bioluminescence imaging and cancer therapy.",
author = "Han, {Xiao Jian} and Sun, {Ling Fei} and Yuki Nishiyama and Bin Feng and Hiroyuki Michiue and Masaharu Seno and Hideki Matsui and Kazuhito Tomizawa",
year = "2013",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.

AU - Han, Xiao Jian

AU - Sun, Ling Fei

AU - Nishiyama, Yuki

AU - Feng, Bin

AU - Michiue, Hiroyuki

AU - Seno, Masaharu

AU - Matsui, Hideki

AU - Tomizawa, Kazuhito

PY - 2013

Y1 - 2013

N2 - A combination of molecular-targeted cancer imaging and therapy is an emerging strategy to improve cancer diagnosis and minimize the side effects of conventional treatments. Here, we generated a recombinant protein, EC1-GLuc-p53C, by fusing EC1 peptide, an artificial ligand of ErbB2, with Gaussia luciferase (GLuc) and a p53-activating peptide, p53C. EC1-GLuc-p53C was expressed and purified from E. coli BL21. In vitro experiments showed that EC1-GLuc-p53c was stable in luminescent activity and selectively targeted ErbB2-overexpressing BT474 cells for bioluminescence imaging. Moreover, the internalized EC1-GLuc-p53C in BT474 cells exerted its function to reactivate p53 and significantly inhibited cellular proliferation. In tumor-bearing mice, the ErbB2-targeted bioluminescence imaging and therapeutic effect of EC1-GLuc-p53C were also observed specifically in BT474 tumors but not in MCF7 tumors, which does not overexpress ErbB2. Thus, the present study demonstrates EC1-GLuc-p53C to be an effective theranostic reagent targeting ErbB2 for bioluminescence imaging and cancer therapy.

AB - A combination of molecular-targeted cancer imaging and therapy is an emerging strategy to improve cancer diagnosis and minimize the side effects of conventional treatments. Here, we generated a recombinant protein, EC1-GLuc-p53C, by fusing EC1 peptide, an artificial ligand of ErbB2, with Gaussia luciferase (GLuc) and a p53-activating peptide, p53C. EC1-GLuc-p53C was expressed and purified from E. coli BL21. In vitro experiments showed that EC1-GLuc-p53c was stable in luminescent activity and selectively targeted ErbB2-overexpressing BT474 cells for bioluminescence imaging. Moreover, the internalized EC1-GLuc-p53C in BT474 cells exerted its function to reactivate p53 and significantly inhibited cellular proliferation. In tumor-bearing mice, the ErbB2-targeted bioluminescence imaging and therapeutic effect of EC1-GLuc-p53C were also observed specifically in BT474 tumors but not in MCF7 tumors, which does not overexpress ErbB2. Thus, the present study demonstrates EC1-GLuc-p53C to be an effective theranostic reagent targeting ErbB2 for bioluminescence imaging and cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84902229243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902229243&partnerID=8YFLogxK

M3 - Article

C2 - 24069396

AN - SCOPUS:84902229243

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e75288

ER -